Ger Rijkers

Professor of Biomedical and Life Sciences, University College Roosevelt, the Netherlands

As a researcher and academic Ger specialises in the interaction between the human immune system and micro-organisms of the respiratory and gastrointestinal tract, immunoregulation, vaccination, and healthy ageing.  In addition to his work at the Roosevelt, he is a medical immunologist and senior scientist at the Laboratory of Medical Microbiology and Immunology at St Antonius Hospital in the Netherlands.   He has published over 300 papers in peer-reviewed scientific journals and edited an E-book on pneumococcal conjugate vaccines.  He is Section Editor for the journal Beneficial Microbes, is co-Editor-in-Chief of Pneumonia and is a member of the Scientific Advisory Board of IPA.

Back to speakers

Probiotic futures:  A global analysis of current clinical trials and what they mean for the industry

On behalf of the IPA, Ger and his team have completed a comprehensive review of over 1,000 probiotics related clinical trials currently underway worldwide (as registered in www.clinical  This gives the industry its first global snapshot of what’s happening in the world of probiotics; the scientific discoveries we can expect to see over the next five years and the product development opportunities they will give rise to. To complete the review, he has interrogated data from the US National Institute of Health and the World Health Organisation (WHO), making this the most both exhaustive and reliable information source available. Studies from countries like Japan, Australia and Iran are mainly posted on the WHO website. He will reveal:

  • What’s happening where – and why Europe has emerged as a global hot spot for probiotic research and innovation
  • What’s coming next –neurodegenerative diseases such as Parkinsons and Alzheimers heads the list of treatment areas currently under scrutiny
  • What’s in it for you – implications for your product development pipeline and why you need to engage with the research now